CytomX Therapeutics (NASDAQ:CTMX) Stock Price Expected to Rise, Barclays Analyst Says

CytomX Therapeutics (NASDAQ:CTMX) had its price objective upped by research analysts at Barclays from $10.00 to $16.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s target price would indicate a potential upside of 259.55% from the stock’s current price.

Several other research firms have also issued reports on CTMX. Guggenheim boosted their price target on CytomX Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday. Piper Sandler lifted their price objective on CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Cantor Fitzgerald boosted their price objective on CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research note on Wednesday, February 4th. HC Wainwright increased their target price on shares of CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Finally, Oppenheimer restated an “outperform” rating and set a $12.00 target price on shares of CytomX Therapeutics in a research note on Monday. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $13.22.

CytomX Therapeutics Price Performance

Shares of CTMX stock opened at $4.45 on Thursday. CytomX Therapeutics has a 1 year low of $0.40 and a 1 year high of $8.21. The firm has a fifty day moving average price of $5.28 and a 200-day moving average price of $4.12. The company has a market cap of $757.35 million, a price-to-earnings ratio of -111.25 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%.The company had revenue of $0.66 million during the quarter, compared to analysts’ expectations of $7.33 million. Equities research analysts expect that CytomX Therapeutics will post -0.05 EPS for the current year.

Insider Activity at CytomX Therapeutics

In other news, insider Yu-Waye Chu sold 21,279 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $136,611.18. Following the completion of the transaction, the insider owned 189,446 shares in the company, valued at $1,216,243.32. This trade represents a 10.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Marcia Belvin sold 31,492 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $202,178.64. Following the completion of the sale, the senior vice president directly owned 300,760 shares in the company, valued at $1,930,879.20. This trade represents a 9.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 191,063 shares of company stock valued at $1,226,624. 6.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CytomX Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC bought a new stake in CytomX Therapeutics in the 3rd quarter worth approximately $25,000. Wells Fargo & Company MN boosted its position in shares of CytomX Therapeutics by 83.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,000 shares during the last quarter. Invesco Ltd. bought a new position in shares of CytomX Therapeutics during the 2nd quarter valued at approximately $32,000. Pursue Wealth Partners LLC purchased a new position in shares of CytomX Therapeutics in the second quarter valued at $33,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in shares of CytomX Therapeutics in the third quarter valued at $34,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Trending Headlines about CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple high‑profile analyst upgrades and big price‑target increases (Jefferies, Barclays, Guggenheim, Wedbush and others) have pushed positive momentum and attracted buyers. Jefferies raises price target to $16
• Positive Sentiment: Trading volume spiked after the analyst upgrade cycle, suggesting the upgrades translated into real buying interest rather than just headlines. Strong trading volume after upgrades
• Neutral Sentiment: CytomX priced an equity offering to raise about $234 million, which materially extends runway and funding for the pipeline but will dilute existing shareholders. Timing and use of proceeds will determine the net effect. Equity offering announcement
• Neutral Sentiment: Short‑interest reports in recent filings show effectively zero reported short interest (data appears inconsistent/NaN), so short positioning is not clearly driving moves at this time. Short interest data (reporting)
• Negative Sentiment: CytomX missed Q1/quarterly estimates on both EPS and revenue, a concrete near‑term negative that increases uncertainty around execution and near‑term cash generation. Shares down on disappointing earnings
• Negative Sentiment: An analyst cut the Q1 EPS forecast, adding to concerns about near‑term financial performance and guidance. Q1 EPS forecast decreased
• Negative Sentiment: Clustered insider selling on March 17 (CEO Sean McCarthy, CFO Christopher Ogden, SVP Marcia Belvin and others) — sizable block sales by multiple senior executives — is dampening sentiment even if some sales are routine. Insider sales report
• Negative Sentiment: Some sell‑side and independent commentary warn that early clinical data may not yet justify elevated valuations, which could pressure momentum traders and cap further upside until clearer clinical/corporate catalysts arrive. Valuation caution commentary

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.